Tulisokibart was linked to clinical, endoscopic and histologic remission in patients with ulcerative colitis following 12 ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

Average dietary fiber intake is lower among patients with active vs inactive inflammatory bowel disease, particularly among ...

SAN DIEGO & COPENHAGEN, Denmark--(BUSINESS WIRE)--AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, announced results ...

Eilean Therapeutics LLC is a biopharmaceutical company focused on the discovery and development of best-in-class and first-in-class small-molecule therapies addressing genetic and signaling ...

Increased vigilance may be warranted among patients with mucosal damage for future Parkinson disease risk. Patients with a history of upper gastrointestinal (GI) mucosal damage have an increased risk ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Experts argued for the development of COVID-19 vaccines ...

Bacteriophages, viruses that infect bacteria, have been shown to preferentially bind to mucosal surfaces. This has been suggested to provide an extra level of immunity against bacterial infections.

Since the early days of the coronavirus pandemic, a niche subset of experimental vaccines has offered the world a tantalizing promise: a sustained slowdown in the spread of disease. Formulated to ...

A research team from the Research Center Borstel, Leibniz Lung Center (FZB), Kiel University (CAU), the University of Lübeck ...